Education
About Us
Working with TipRanks
Follow Us
Relay Therapeutics (RLAY)
NASDAQ:RLAY
RLAY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.78 - $10.72
Previous CloseN/A
Volume391.09K
Average Volume (3M)2.84M
Market Cap
$496.70M
Enterprise Value-$43.39M
Total Cash (Recent Filing)$124.29M
Total Debt (Recent Filing)$48.50M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
May 01, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding169,521,850
10 Day Avg. Volume3,219,062
30 Day Avg. Volume2,842,375
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)51.84
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.34
Enterprise Value/Ebitda0.11
Forecast
1Y Price Target
$15.38Price Target Upside424.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Cash Reserves And Financial PlanningThe company reported cash and cash equivalents of $781mn, which they estimate provides cash runway to the second half of 2027.
Clinical Trial AdvancementsThe combination of RLY-2608 and Faslodex achieved a 38.7% objective response rate in patients with PIK3CA-mutant, HR+/HER2- metastatic breast cancer, indicating promising efficacy.
Drug Development And InnovationRelay Therapeutics Inc is gaining attention due to its innovative approach in drug development.
Bears Say
Competitive LandscapeThe competitive landscape in the biotechnology sector poses a challenge for Relay Therapeutics' market position.
Equity Raises And Financial SustainabilityAnalyst continues to model multiple serial equity raises to fund the advancing pipeline and commercial infrastructure.
Operational ChallengesThe delay in the early pipeline has led to a decrease in the price target from $18 to $14.
---
Ownership Overview
2.91% Insiders
16.94% Mutual Funds
0.16% Other Institutional Investors
64.75% Public Companies and
Individual Investors
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $1.77 and its highest was $10.72 in the past 12 months.
What is Relay Therapeutics’s market cap?
Relay Therapeutics’s market cap is $496.70M.
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 7 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on Feb 26, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.561 by $0.111.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -0.49.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 169,521,850 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.561. Following the earnings report the stock price went down -13.333%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Currently, no hedge funds are holding shares in RLAY
---
Relay Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.38 (424.91% Upside)
$15.38 (424.91% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 27.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.75%
12-Months-Change
Fundamentals
Return on Equity
-44.15%
Trailing 12-Months
Asset Growth
3.24%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
---
RLAY Stock 12 Month Forecast
Average Price Target
$15.38
▲(424.91% Upside)
Technical Analysis
Precigen
―
Theravance Biopharma
―
Keros Therapeutics
―
Tyra Bioscience
―
Sionna Therapeutics, Inc.
―
Best Analysts Covering RLAY
1 Year
1 Year Success Rate
0/27 ratings generated profit
1 Year Average Return
-41.91%
reiterated a buy rating 2 months ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -41.91% per trade.
---